UCB reports new BIMZELX (bimekizumab) data at AAD 2026, showing durable remission in plaque psoriasis and sustained 3-year symptom control in hidradenitis suppurativa.
Written By: Karthik Teja Macharla PharmD, and
Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
UCB presented new data for BIMZELX (bimekizumab-bkzx) at the American Academy of Dermatology Annual Meeting 2026, highlighting durable disease control across two chronic inflammatory skin conditions moderate-to-severe plaque psoriasis and hidradenitis suppurativa (HS).
Plaque psoriasis BE RADIANT and BE VIVID Trials
In plaque psoriasis, post hoc analyses from the Phase 3 BE RADIANT (NCT03536884) and BE VIVID trials (NCT03370133) showed that 62.6% and 64.9% of patients achieved National Psoriasis Foundation (NPF)-defined on-treatment remission a stringent endpoint requiring complete skin clearance sustained for at least six months within the first year of treatment.
Additional long-term data demonstrated the robustness of response even after treatment interruption. Among patients who relapsed after discontinuation, 63.1% regained complete skin clearance (PASI 100) within 12 weeks of retreatment, and 83.6% maintained PASI 100 at four years, underscoring the potential to re-establish disease control without compromising long-term outcomes.
Commenting on these findings, Donatello Crocetta, Chief Medical Officer, UCB highlighted that bimekizumab supports sustained inflammation control and complete skin clearance, with data showing that patients can regain high response rates after treatment interruption without compromising long-term outcomes.
Hidradenitis suppurativa BE HEARD EXT Trial
In hidradenitis suppurativa, new analyses from the BE HEARD extension program (NCT04901195) showed durable symptom control through three years of treatment. Notably, 86.1% of patients experienced no acute disease flares at scheduled visits up to three years, highlighting sustained disease stability.
Clinical response rates further reinforced the benefit of early intervention. Patients with shorter disease duration and moderate baseline severity achieved HiSCR90 and HiSCR100 responses of 74.1% and 62.1%, respectively, compared with lower response rates in those with long-standing, severe disease.
Across subgroup analyses including age, body mass index, sex, and baseline disease severity consistent efficacy was observed, with improvements maintained over three years, supporting the broad applicability of bimekizumab in HS management.
Steven Daveluy, Department of Dermatology, Wayne State University School of Medicine, noted that hidradenitis suppurativa flares place a significant burden on patients, and highlighted that bimekizumab demonstrated durable long-term control, with nearly 90% of patients remaining flare-free at scheduled visits for up to three years.
Collectively, these findings presented at AAD 2026 reinforce BIMZELX’s potential to deliver deep, durable disease control, with high rates of complete skin clearance in psoriasis and sustained symptom suppression in hidradenitis suppurativa, particularly when treatment is initiated earlier in the disease course.
References
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis, 27 March 2026, UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis | UCB
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa, 27 March 2026, UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa | UCB
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.